Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Spectrum Pharmaceuticals
So what: The decision marks a welcome vindication for Fusilev, which the FDA initially denied, eventually concluding it was an effective enough treatment following an October 2009 submission. Eighteen months later, the drug will now see its way to patients in need.
Now what: For investors, the ruling means that Spectrum now has two approved cancer treatments in its biotech portfolio. The other, lymphoma drug Zevalin, helped Spectrum nearly double revenues in 2010. Asking the same this year may be asking too much, but there's little doubt this growth story is getting going.
Interested in more info on Spectrum Pharmaceuticals? Add it to your watchlist.
Tim didn't own shares in any of the companies mentioned in this article at the time of publication. Check out his portfolio holdings and Foolish writings, or connect with him on Twitter as @milehighfool. You can also get his insights delivered directly to your RSS reader. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool is also on Twitter as @TheMotleyFool. Its disclosure policy is at least 10% better than other disclosure policies.